Oral delivery of oligonucleotides
NZ835116APending Publication Date: 2026-07-31CIVI BIOPHARMA INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ835116
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-10
- Filing Date
- 2022-04-21
- Publication Date
- 2026-07-31
Smart Images

Figure 00000215_0000 
Figure 00000215_0001 
Figure 00000216_0000
Abstract
The present disclosure provides oligonucleotide compositions comprising (1) an oligonucleotide of the present disclosure, e.g., an ASO, siRNA, shRNA, DNA or RNA aptamer, gene therapy vector, miRNA, miRNA mimic, antimiR, DNA or RNA decoy, CpG oligonucleotide, or any therapeutic or diagnostic oligonucleotide known in the art, and (ii) a caprylic acid derivative, e.g., 5-CNAC. In some aspects, the oligonucleotide composition is formulated for delivery to the gastrointestinal tract. Thus, some aspects, the present disclosure provides oligonucleotide compositions for oral delivery comprising a therapeutic or diagnostic oligonucleotide (e.g., an ASO) and a caprylic acid derivative (e.g., 5-CNAC or de derivative thereof).
Need to check novelty before this filing date? Find Prior Art